Immuno-Oncology Outlook: Looking For Brain Cancer Options
Executive Summary
Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.
You may also be interested in...
Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.